iSAM Funds UK Ltd Makes New Investment in Cencora, Inc. (NYSE:COR)

iSAM Funds UK Ltd acquired a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,955 shares of the company's stock, valued at approximately $1,113,000. Cencora comprises 0.8% of iSAM Funds UK Ltd's holdings, making the stock its 23rd largest holding.

Several other hedge funds have also recently modified their holdings of the stock. JFS Wealth Advisors LLC lifted its stake in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Cencora in the fourth quarter worth about $29,000. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora in the fourth quarter worth about $30,000. Kentucky Trust Co purchased a new stake in shares of Cencora in the fourth quarter worth about $33,000. Finally, WASHINGTON TRUST Co boosted its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock valued at $13,580,967 in the last 90 days. Company insiders own 10.80% of the company's stock.

Cencora Stock Up 0.7%

Shares of NYSE:COR opened at $292.37 on Tuesday. The firm has a market capitalization of $56.70 billion, a PE ratio of 41.59, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The business has a 50 day simple moving average of $279.87 and a two-hundred day simple moving average of $255.76. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $309.35. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Cencora's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $3.80 EPS. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's payout ratio is presently 25.52%.

Analysts Set New Price Targets

Several analysts have recently issued reports on COR shares. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. UBS Group upped their price target on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Bank of America boosted their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Finally, Morgan Stanley set a $288.00 price objective on Cencora in a research note on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $301.18.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.